D. E. Shaw & Co. Inc. Has $10.03 Million Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

D. E. Shaw & Co. Inc. increased its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 172.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,151,195 shares of the company's stock after purchasing an additional 727,987 shares during the period. D. E. Shaw & Co. Inc. owned 1.48% of Kura Oncology worth $10,027,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. DAFNA Capital Management LLC grew its holdings in Kura Oncology by 9.8% during the 4th quarter. DAFNA Capital Management LLC now owns 448,368 shares of the company's stock worth $3,905,000 after acquiring an additional 40,000 shares during the period. Corton Capital Inc. acquired a new stake in shares of Kura Oncology during the fourth quarter worth $99,000. BNP Paribas Financial Markets grew its stake in shares of Kura Oncology by 969.9% during the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company's stock worth $1,425,000 after purchasing an additional 148,272 shares during the period. Ameriprise Financial Inc. bought a new stake in Kura Oncology in the fourth quarter valued at about $130,000. Finally, Alethea Capital Management LLC lifted its stake in Kura Oncology by 0.9% in the fourth quarter. Alethea Capital Management LLC now owns 558,442 shares of the company's stock valued at $4,864,000 after buying an additional 4,900 shares during the period.

Kura Oncology Stock Up 1.7%

NASDAQ:KURA traded up $0.11 on Tuesday, hitting $6.35. 243,794 shares of the company's stock were exchanged, compared to its average volume of 1,425,001. The firm has a 50-day moving average price of $6.39 and a 200-day moving average price of $8.65. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market cap of $549.32 million, a P/E ratio of -2.69 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. As a group, analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on KURA. StockNews.com cut Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a report on Tuesday, April 8th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Mizuho decreased their price objective on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday. Finally, JMP Securities restated a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.